Wangshan Wangshui-B (02630) announced interim results. Shareholders' losses of 122 million yuan decreased by 29.4% year-on-year

According to the Zhitong Finance App, Wangshan Wangshui-B (02630) announced interim results for the six months ended June 30, 2026. The group achieved revenue of 132 million yuan, an increase of 693.7% over the previous year; losses due to company owners were 122 million yuan, a year-on-year decrease of 29.4%; and a basic loss of 0.73 yuan per share.

According to the announcement, the increase in revenue was mainly due to the Group's commercialization of a new drug in July 2025, and sales of the drug continued to rise, and revenue increased by 107 million yuan; and in December 2025, the Group officially signed a license agreement with the customer for the new indications of VV116, and received a milestone payment of 20 million yuan in the first half of 2026.